The FSE Group

Momentum Bioscience develops rapid in vitro diagnostic tests for critically important clinical specimens. Its technologies include ETGA, which provides ultrasensitive, rapid, and universal detection of all bacterial and fungal species while identifying only viable organisms. Through Enzyme Mediated Amplification, the company aims to rapidly detect infections in blood and other normally sterile body fluids, enabling universal detection of viable bacteria and fungi in under two hours, far faster than conventional methods. The company offers a suite of related systems for rapid detection of infection in neonatal, emergency, and critical-care settings. Momentum Bioscience was established in 2005 and is based in Cardiff, United Kingdom.

Momentum Bioscience develops rapid in vitro diagnostic tests for critically important clinical specimens. Its technologies include ETGA, which provides ultrasensitive, rapid, and universal detection of all bacterial and fungal species while identifying only viable organisms. Through Enzyme Mediated Amplification, the company aims to rapidly detect infections in blood and other normally sterile body fluids, enabling universal detection of viable bacteria and fungi in under two hours, far faster than conventional methods. The company offers a suite of related systems for rapid detection of infection in neonatal, emergency, and critical-care settings. Momentum Bioscience was established in 2005 and is based in Cardiff, United Kingdom.

Momentum Bioscience develops rapid in vitro diagnostic tests for critically important clinical specimens. Its technologies include ETGA, which provides ultrasensitive, rapid, and universal detection of all bacterial and fungal species while identifying only viable organisms. Through Enzyme Mediated Amplification, the company aims to rapidly detect infections in blood and other normally sterile body fluids, enabling universal detection of viable bacteria and fungi in under two hours, far faster than conventional methods. The company offers a suite of related systems for rapid detection of infection in neonatal, emergency, and critical-care settings. Momentum Bioscience was established in 2005 and is based in Cardiff, United Kingdom.